Biopharmaceutical companies are integrating predictive analytics into phase-two clinical trial protocols, significantly reducing trial initiation phases. Cohort identification models analyze historical electronic health records to target viable patient demographics.
Recruitment Velocity
Traditional recruitment delays historically account for nearly 40 percent of overall clinical trial schedules. Automated screening systems have reduced candidate drop-out rates while improving compliance with complex biomarker inclusion criteria.